|
1.
|
|
|
2.
|
|
14 p, 4.7 MB |
Safety and Efficacy upon Infection in Sheep with Rift Valley Fever Virus ZH548-rA2, a Triple Mutant Rescued Virus
/
Moreno, Sandra (Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria. Centro de Investigación en Sanidad Animal) ;
Lorenzo, Gema (Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria. Centro de Investigación en Sanidad Animal) ;
López-Valiñas, Álvaro (Unitat mixta d'investigació IRTA-UAB en Sanitat Animal. Centre de Recerca en Sanitat Animal) ;
de la Losa, Nuria (Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria. Centro de Investigación en Sanidad Animal) ;
Alonso, Celia (Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria. Centro de Investigación en Sanidad Animal) ;
Charro, Elena (Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria. Centro de Investigación en Sanidad Animal) ;
Núñez, J. Ignacio (Unitat mixta d'investigació IRTA-UAB en Sanitat Animal. Centre de Recerca en Sanitat Animal) ;
Sánchez-Cordón, Pedro J. (Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria. Centro de Investigación en Sanidad Animal) ;
Borrego, Belén (Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria. Centro de Investigación en Sanidad Animal) ;
Brun, Alejandro (Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria. Centro de Investigación en Sanidad Animal)
The introduction of three single nucleotide mutations into the genome of the virulent RVFV ZH548 strain allows for the rescue of a fully attenuated virus in mice (ZH548-rA2). These mutations are located in the viral genes encoding the RdRp and the non-structural protein NSs. [...]
2024 -  10.3390/v16010087
Viruses, Vol. 16 (january 2024)
|
|
|
3.
|
|
17 p, 1.2 MB |
Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia : A Matching Adjusted Indirect Comparison
/
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Prawitz, Thibaud (Evidera Inc) ;
Freitag, Andreas (Evidera Inc) ;
Sharma, Anuj (Evidera Inc) ;
Dobi, Balázs (Evidera Inc) ;
Rizzo, Federica (Incyte Biosciences International Sàrl, Morges, Switzerland) ;
Sabatelli, Lorenzo (Incyte Biosciences International Sàrl, Morges, Switzerland) ;
Patos, Petros (Incyte Biosciences International Sàrl, Morges, Switzerland)
Introduction: Efficacy of ponatinib-based treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) has not been compared to imatinib-based treatments in head-to-head clinical trials. [...]
2023 - 10.1007/s12325-023-02497-y
Advances in Therapy, Vol. 40 Núm. 7 (july 2023) , p. 3087-3103
|
|
|
4.
|
|
|
5.
|
|
9 p, 544.7 KB |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI) : A Multicenter Randomized Open-Label Study (PReEC/RIS-57)
/
Podzamczer, Daniel (Hospital Universitari de Bellvitge) ;
Micán, R. (Hospital Universitario La Paz (Madrid)) ;
Tiraboschi, Juan Manuel (Hospital Universitari de Bellvitge) ;
Portilla, J. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ;
Llibre, Josep M.. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ribera, E. (Hospital Universitari Vall d'Hebron) ;
Vivancos, M.J. (Hospital Universitario Ramón y Cajal (Madrid)) ;
Morano, L. (Hospital Álvaro Cunqueiro (Vigo)) ;
Masiá, M. (Hospital General Universitario de Elche) ;
Gómez, C. (Hospital Universitario Virgen de la Victoria-IBIMA) ;
Fanjul, F. (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Payeras, A. (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Inciarte, Alexy (Hospital Clínic i Provincial de Barcelona) ;
Estrada, V. (Hospital Clínico San Carlos-IdiSSC) ;
Rivero, A. (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Castro, A. (Complejo Hospitalario Universitario) ;
Bernal, Enrique (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Vinuesa, D. (Hospital Universitario San Cecilio (Granada)) ;
Knobel Freud, Hernando (Hospital del Mar (Barcelona, Catalunya)) ;
Troya, J. (Hospital Universitario Infanta Leonor) ;
Macías, Juan (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ;
Montero, M. (Hospital Universitari i Politècnic La Fe (València)) ;
Sanz, J. (Hospital Universitario de la Princesa (Madrid)) ;
Navarro-Alcaraz, Antonio (Hospital Universitari de Bellvitge) ;
Caicedo, A. (Ris Red de Investigación en Sida) ;
Fernández, G. (Hospital Universitari de Bellvitge) ;
Martínez, Esteban (Hospital Clínic i Provincial de Barcelona) ;
Moreno, S. (Hospital Universitario Ramón y Cajal (Madrid)) ;
Universitat Autònoma de Barcelona
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is the reference for combination therapy based on protease inhibitors due to its efficacy, tolerability, and convenience. Head-to-head randomized comparisons between D/C/F/TAF and combination therapy based on integrase inhibitors in antiretroviral-naive patients are lacking. [...]
2022 - 10.1093/ofid/ofab595
Open Forum Infectious Diseases, Vol. 9 Núm. 3 (january 2022) , p. ofab595
|
|
|
6.
|
|
8 p, 789.9 KB |
Long-term efficacy and safety of brodalumab in the treatment of psoriasis : 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial
/
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Lebwohl, Mark (Icahn School of Medicine at Mount Sinai) ;
Bachelez, Hervé (AP-HP Hôpital Saint-Louis) ;
Sobell, Jeffrey (SkinCare Physicians) ;
Jacobson, Abby A. (Ortho Dermatologics) ;
Universitat Autònoma de Barcelona
Randomized controlled trials have shown the efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis. To evaluate the efficacy and safety of brodalumab through 120 weeks of treatment in the AMAGINE-2 trial. [...]
2020 - 10.1016/j.jaad.2019.05.095
Journal of the American Academy of Dermatology, Vol. 82 Núm. 2 (february 2020) , p. 352-359
|
|
|
7.
|
|
8 p, 664.2 KB |
Exposure-response modeling of cabozantinib in patients with renal cell carcinoma : Implications for patient care
/
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Benzaghou, Fawzi (Ipsen Pharma) ;
Taguieva, Naila (Ipsen Pharma) ;
Nguyen, Linh (Exelixis. Inc.) ;
Clary, Douglas O. (Exelixis. Inc.) ;
Jonasch, Eric W. (The University of Texas MD Anderson Cancer Center) ;
Universitat Autònoma de Barcelona
Cabozantinib is an oral tyrosine kinase inhibitor (TKI) approved for the treatment of patients with advanced renal cell carcinoma (RCC) at a dose of 60 mg/day. As with other TKIs, cabozantinib is associated with high interpatient variability in drug clearance and exposure that can significantly impact safety and tolerability across a patient population. [...]
2020 - 10.1016/j.ctrv.2020.102062
Cancer Treatment Reviews, Vol. 89 (september 2020) , p. 102062
|
|
|
8.
|
|
19 p, 1.1 MB |
Vortioxetine in major depressive disorder : from mechanisms of action to clinical studies. An updated review
/
de Diego-Adeliño, Javier (Institut d'Investigació Biomèdica Sant Pau) ;
Crespo, José Manuel (Complejo Hospitalario Universitario de Ferrol) ;
Mora, Fernando (Hospital Universitario Infanta Leonor) ;
Neyra, Adrián (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Iborra, Pedro (Hospital Universitario San Juan de Alicante) ;
Gutiérrez-Rojas, Luis (Hospital Universitario San Cecilio (Granada)) ;
Salonia, Selman F. (Centro de Salud Mental de Jumilla) ;
Universitat Autònoma de Barcelona
Introduction: Vortioxetine is a multimodal-acting antidepressant that provides improvements on cognitive function aside from antidepressants and anxiolytic effects. Vortioxetine has been found to be one of the most effective and best tolerated options for major depressive disorder (MDD) in head-to-head trials. [...]
2022 - 10.1080/14740338.2022.2019705
Expert Opinion on Drug Safety, Vol. 21 Núm. 5 (2022) , p. 673-690
|
|
|
9.
|
|
19 p, 537.2 KB |
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis : Up to 5 years of follow-up in the DAYBREAK open-label extension trial
/
Cree, Bruce A. C (University of California) ;
Selmaj, Krzysztof W. (University of Warmia and Mazury in Olsztyn) ;
Steinman, Lawrence (Stanford University) ;
Comi, Giancarlo (Vita-Salute San Raffaele University) ;
Bar-Or, Amit (University of Pennsylvania) ;
Arnold, Douglas Lorne (McGill University) ;
Hartung, Hans-Peter (Medical University of Vienna) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Kubala Havrdova, Eva (Charles University) ;
Sheffield, James K. (Bristol-Myers Squibb Company) ;
Minton, Neil (Bristol-Myers Squibb Company) ;
Cheng, Chun Yen (Bristol-Myers Squibb Company) ;
Silva, Diego (Bristol-Myers Squibb Company) ;
Kappos, Ludwig (University of Basel) ;
Cohen, Jeffrey A. (Cleveland Clinic) ;
Universitat Autònoma de Barcelona
Background: Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple countries for treatment of relapsing forms of MS. Objective: To characterize long-term safety and efficacy of ozanimod. [...]
2022 - 10.1177/13524585221102584
Multiple sclerosis, Vol. 28 Núm. 12 (2022) , p. 1944-1962
|
|
|
10.
|
|
11 p, 1.0 MB |
STIG study : real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa
/
Gutschmidt, K. (Department of Neurology. Friedrich-Baur-Institute. Ludwig-Maximilians University Munich) ;
Musumeci, O. (Department of Clinical and Experimental Medicine. University of Messina) ;
Diaz-Manera, Jordi (Institut d'Investigació Biomèdica Sant Pau) ;
Chien, Y.H. (Department of Medical Genetics and Pediatrics. National Taiwan University Hospital) ;
Knop, K.C. (Neurologische Praxis Neuer Wall) ;
Wenninger, S. (Department of Neurology. Friedrich-Baur-Institute. Ludwig-Maximilians University Munich) ;
Montagnese, F. (Department of Neurology. Friedrich-Baur-Institute. Ludwig-Maximilians University Munich) ;
Pugliese, A. (Department of Clinical and Experimental Medicine. University of Messina) ;
Tavilla, G. (Department of Clinical and Experimental Medicine. University of Messina) ;
Alonso-Pérez, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Hwu, P.W.L. (Department of Medical Genetics and Pediatrics. National Taiwan University Hospital) ;
Toscano, A. (Department of Clinical and Experimental Medicine. University of Messina) ;
Schoser, B. (Department of Neurology. Friedrich-Baur-Institute. Ludwig-Maximilians University Munich)
Background: Pompe disease is one of the few neuromuscular diseases with an approved drug therapy, which has been available since 2006. Our study aimed to determine the real-world long-term efficacy and safety of alglucosidase alfa. [...]
2021 - 10.1007/s00415-021-10409-9
Journal of Neurology, Vol. 268 Núm. 7 (july 2021) , p. 2482-2492
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
